AR027098A1 - Derivados sustituidos del acido n-bencil-indol-3-il-glioxilico con efecto antitumoral, sus sales, las composiciones farmaceuticas que los contienen y lautilizacion de las mismas para preparar medicamentos - Google Patents

Derivados sustituidos del acido n-bencil-indol-3-il-glioxilico con efecto antitumoral, sus sales, las composiciones farmaceuticas que los contienen y lautilizacion de las mismas para preparar medicamentos

Info

Publication number
AR027098A1
AR027098A1 ARP000106916A ARP000106916A AR027098A1 AR 027098 A1 AR027098 A1 AR 027098A1 AR P000106916 A ARP000106916 A AR P000106916A AR P000106916 A ARP000106916 A AR P000106916A AR 027098 A1 AR027098 A1 AR 027098A1
Authority
AR
Argentina
Prior art keywords
salts
formula
acid
substituted derivatives
lautilization
Prior art date
Application number
ARP000106916A
Other languages
English (en)
Spanish (es)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of AR027098A1 publication Critical patent/AR027098A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
ARP000106916A 1999-12-23 2000-12-22 Derivados sustituidos del acido n-bencil-indol-3-il-glioxilico con efecto antitumoral, sus sales, las composiciones farmaceuticas que los contienen y lautilizacion de las mismas para preparar medicamentos AR027098A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19962300A DE19962300A1 (de) 1999-12-23 1999-12-23 Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung

Publications (1)

Publication Number Publication Date
AR027098A1 true AR027098A1 (es) 2003-03-12

Family

ID=7934006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106916A AR027098A1 (es) 1999-12-23 2000-12-22 Derivados sustituidos del acido n-bencil-indol-3-il-glioxilico con efecto antitumoral, sus sales, las composiciones farmaceuticas que los contienen y lautilizacion de las mismas para preparar medicamentos

Country Status (31)

Country Link
US (1) US6432987B2 (https=)
EP (1) EP1240157B1 (https=)
JP (1) JP2003519137A (https=)
KR (1) KR100747425B1 (https=)
CN (1) CN1283637C (https=)
AR (1) AR027098A1 (https=)
AT (1) ATE259364T1 (https=)
AU (1) AU772745B2 (https=)
BG (1) BG106924A (https=)
BR (1) BR0016712A (https=)
CA (1) CA2395259A1 (https=)
CO (1) CO5251472A1 (https=)
CZ (1) CZ20022094A3 (https=)
DE (2) DE19962300A1 (https=)
DK (1) DK1240157T3 (https=)
ES (1) ES2215768T3 (https=)
HK (1) HK1054038B (https=)
HU (1) HUP0203716A3 (https=)
IL (1) IL150235A0 (https=)
MX (1) MXPA02006229A (https=)
NO (1) NO324750B1 (https=)
NZ (2) NZ533731A (https=)
PL (1) PL195014B1 (https=)
PT (1) PT1240157E (https=)
RU (1) RU2266280C2 (https=)
SK (1) SK8752002A3 (https=)
TR (1) TR200400601T4 (https=)
TW (1) TWI284128B (https=)
UA (1) UA75060C2 (https=)
WO (1) WO2001047913A2 (https=)
ZA (1) ZA200204896B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
BRPI0410998A (pt) * 2003-06-05 2006-07-04 Zentaris Gmbh derivados de indol com efeito de indução de apoptose
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP5385605B2 (ja) * 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセットトランスポーターのモジュレーター
US8884020B2 (en) * 2006-08-07 2014-11-11 Ironwood Pharmaceuticals, Inc. Indole compounds
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
CA2135160A1 (en) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Indole derivative
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DK0746544T3 (da) * 1994-02-22 1999-06-07 Merrell Pharma Inc Indolderivater til behandling af østrogenafhængige neoplasmer og sygdomme
BR9501404A (pt) * 1994-04-01 1996-03-05 Lilly Co Eli 1H-indol-3 glioxilamida e formulação farmacèutica
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
AU1200799A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company Isopropyl ester prodrugs of indole spla2 inhibitors
ES2241178T3 (es) * 1997-10-27 2005-10-16 Eli Lilly And Company Profarmacos de ester de morlino-n-etilo de inhibidores indolicos de spla 2.
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
AU1405899A (en) * 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
EE200000488A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
TR200003130T2 (tr) * 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
BR9910095A (pt) * 1998-05-01 2000-12-26 Lilly Co Eli Compostos inibidores de spla2 para tratamento de doença
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action

Also Published As

Publication number Publication date
US6432987B2 (en) 2002-08-13
PT1240157E (pt) 2004-06-30
EP1240157B1 (de) 2004-02-11
JP2003519137A (ja) 2003-06-17
ATE259364T1 (de) 2004-02-15
TR200400601T4 (tr) 2004-04-21
IL150235A0 (en) 2002-12-01
WO2001047913A3 (de) 2002-04-25
NO20023039L (no) 2002-08-09
DE19962300A1 (de) 2001-06-28
BR0016712A (pt) 2002-09-03
WO2001047913A2 (de) 2001-07-05
NZ519977A (en) 2004-08-27
PL355684A1 (en) 2004-05-17
KR100747425B1 (ko) 2007-08-09
NO20023039D0 (no) 2002-06-21
NZ533731A (en) 2005-03-24
RU2002120462A (ru) 2004-01-10
CN1283637C (zh) 2006-11-08
CA2395259A1 (en) 2001-07-05
DK1240157T3 (da) 2004-06-14
CN1420880A (zh) 2003-05-28
MXPA02006229A (es) 2003-01-28
SK8752002A3 (en) 2003-01-09
HUP0203716A2 (hu) 2003-03-28
KR20020063245A (ko) 2002-08-01
RU2266280C2 (ru) 2005-12-20
ZA200204896B (en) 2002-12-20
EP1240157A2 (de) 2002-09-18
BG106924A (bg) 2003-04-30
US20010014690A1 (en) 2001-08-16
ES2215768T3 (es) 2004-10-16
NO324750B1 (no) 2007-12-03
AU2011901A (en) 2001-07-09
HUP0203716A3 (en) 2004-05-28
UA75060C2 (en) 2006-03-15
AU772745B2 (en) 2004-05-06
HK1054038B (zh) 2007-04-13
DE50005284D1 (de) 2004-03-18
CO5251472A1 (es) 2003-02-28
PL195014B1 (pl) 2007-07-31
TWI284128B (en) 2007-07-21
HK1054038A1 (en) 2003-11-14
CZ20022094A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
AR027098A1 (es) Derivados sustituidos del acido n-bencil-indol-3-il-glioxilico con efecto antitumoral, sus sales, las composiciones farmaceuticas que los contienen y lautilizacion de las mismas para preparar medicamentos
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
UY27891A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparación de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos.
UY26962A1 (es) Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
BRPI0513086A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos
ECSP034831A (es) Derivados sustituidos de la 2-piridina ciclohexano-1,4-diamina
ES2054995T3 (es) Nuevos derivados del acido benzoico y acido fenilacetico, su obtencion y empleo como medicamentos.
ES2054988T3 (es) Quinuclidinas, su empleo como medicamentos y procedimiento para su produccion.
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
CL2003002611A1 (es) Compuestos derivados del acido tiofeno hidroxamico, 2-hidroxamida-5-[(aril o heteroaril)-disutituido-metil]-amida del acido tiofeno-2,5-dicarboxilico enantiomeros, composicion farmaceutica, procedimiento de preparacion, y su uso para el tratamiento d
ES483792A1 (es) Un procedimiento para la preparacion de derivados de tetra- zolilalcoxicarbostirilo.
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
ES2179094T3 (es) Derivados de amidas ciclicas como antagonistas de la neuroquinina a.
UY28482A1 (es) Nuevos compuestos
PA8680701A1 (es) Derivados de oxindol
ECSP099320A (es) Compuestos de tetrahidropirrolopiracina sustituida y su aplicación en medicamentos
SV1999000048A (es) Uso de dihidropiriminas como medicamento y nuevas sustancias ref. lea 32 791-sv
ES2123810T3 (es) Heterociclos utiles como antagonistas de neuroquinina.
ES2178779T3 (es) Nuevas amidas de acidos de piridil alcanos como agentes citoestaticos e inmunosupresores.
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
SE8400332L (sv) Forening for anvendning som mellanprodukt vid framstellning av lekemedel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal